NCT06843044

Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders

An Open-label, Comparative, Randomized, Multicenter Phase IV Clinical Study to Evaluate the Clinical Efficacy and Safety of the Drug Ranquilon, Tablets, 1 mg, in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 250 (estimated)
• Sponsor: Valenta Pharm JSC · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Study is to evaluate the efficacy and safety of the drug Ranquilon, 1 mg tablets, at a dosage of 6 mg/day compared to the drug Afobazole, 10 mg tablets, at a dosage of 30 mg/day for the treatment of patients with anxiety disorders due to neurasthenia and adjustment disorders.

Conditions

• Anxiety
• Neurasthenia
• Adjustment Disorders

Interventions

Type	Name	Description
DRUG	Ranquilon	1 mg tablets
DRUG	Afobazole	10 mg tablets

Timeline

• Start date: 2025-01-13
• Primary completion: 2027-12-31
• Completion: 2027-12-31
• First posted: 2025-02-24
• Last updated: 2025-07-08

Locations

6 sites across 1 country: Russia